Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
GLP-1s reduce inflammatory markers like CRP and IL-6
The recent Semaglutide Cardiovascular Outcomes Trial (SOUL) reported that once-daily oral semaglutide (maximal dose, 14 mg), in addition to standard care, significantly reduces the risk of MACE in individuals with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, without an increase in the incidence of serious adverse events [6]
It was the recurring theme in the discussion: patient demand for these therapies already exists
Surgical patients are accepted from across the United States
US$ 29.49
US$ 25.58
US$ 24.72
